Abstract
The benefits of surgical resection for patients with stage N2 limited-disease small-cell lung cancer (LD-SCLC) remain controversial. This retrospective study analyzed the survival and recurrence patterns of the patients diagnosed with pathological N2 (p-N2) LD-SCLC after radical resection. A total of 171 p-N2 LD-SCLC patients who underwent radical pulmonary resection and systematic lymphadenectomies at Shanghai Chest Hospital from July 2005 to June 2015 were enrolled. The influence of the mediastinal lymph node status (single or multiple nodes, single- or multiple-station) on the survival and recurrence patterns was retrospectively analyzed. The main recurrence sites were outside the chest cavity (54.8%) and hematogenous metastasis (67.4%). The bone and liver as initial recurrence sites had a poor prognosis, with a median overall survival (OS) of 13.100 months and 11.900 months, respectively. The median disease-free survival (DFS) of patients diagnosed with single and multiple p-N2 after surgery were 19.233 and 9.367 months (P = 0.001), and the median OS were 43.033 and 17.100 months (P < 0.001), respectively. In conclusion, recurrence occurred in the form of hematogenous metastasis mostly in the extra-thoracic part. Interestingly, patients diagnosed with single p-N2 benefited from radical resection. Surgery may be a treatment option regardless of the T stage if N2 SCLC with a single metastatic lymph node can be identified preoperatively.
Highlights
Tobacco-control measures have led to a decline in the incidence and mortality of lung cancer over the past decades, this cancer remains to be among the leading causes of cancer mortality worldwide [1, 2]
Concurrent chemoradiotherapy is the standard of care in the rest of limited disease Small-cell lung cancer (SCLC) (LD-SCLC) instead of radical surgery, especially in patients diagnosed with lymph node metastasis (N1-N2) [7]
There are few studies focused on the lymph node status of the patients diagnosed with pathological N2 (p-N2) SCLC, whether they could benefit from radical surgery or chemoradiotherapy
Summary
Tobacco-control measures have led to a decline in the incidence and mortality of lung cancer over the past decades, this cancer remains to be among the leading causes of cancer mortality worldwide [1, 2]. Two randomized phase III studies conducted in the 1960s [5] and the 1980s [6] reported negative results with surgery in limiteddisease SCLC (LD-SCLC) patients and, thereafter, surgery has been discouraged. The aforementioned studies were critical in shaping treatment recommendations for LD-SCLC. The International Guidelines highlight that surgery is justified for selected stage I (T1-2,N0M0) SCLC patients, after adequate staging. Concurrent chemoradiotherapy is the standard of care in the rest of limited disease SCLC (LD-SCLC) instead of radical surgery, especially in patients diagnosed with lymph node metastasis (N1-N2) [7]. There are few studies focused on the lymph node status of the patients diagnosed with pathological N2 (p-N2) SCLC, whether they could benefit from radical surgery or chemoradiotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
